News and Comments

Biomarin Decision Might Add More Stress Than Put Pressure on the FDA to Approve Sarepta Drug

  Thursday, June 02, 2016

Biomarin Pharmaceutical’s (BMRN) decision to withdraw its DMD drug Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) means more than pressuring the FDA to approve Sarepta’s DMD product eteplirsen.  More...

IONIS Stock Selloff: Has GSK Abandoned the Wagon or Jumped Out of the Train? See Also: Osteoporosis

  Friday, May 27, 2016


Great News for Innoviva and COPD Patients

  Wednesday, May 25, 2016

GlaxoSmithKline and Innoviva: The COPD inhaler Relvar® Ellipta® (known as Brio Ellipta in the United States) Demonsterates Superiority Over Usual Care. More...

Exelixis: Results Demonstrate the Potential of Cabozantinib to Become the Gold Standard First Line Treatment for Advanced RCC

  Monday, May 23, 2016

Yes, indeed, the good news has come from the randomized CABOSUN phase 2 trial with Exelixis’ (EXEL) drug cabozantinib. The news is indirectly telling us that Cabozantinib may soon become the first-line treatment for previously untreated advanced renal cell carcinoma (RCC).  More...

Biogen: A Fruitful Collaboration in Gene Therapy. A Small Gene Therapy Firm That You Should Know

  Tuesday, May 17, 2016


Seres Therapeutics Collaborates with Memorial Sloan Kettering Cancer Center to Improve Immunotherapy

  Friday, May 13, 2016

Seres Therapeutics (MCRB), is microbiome therapeutics platform company. It focuses on developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced.  More...

Exelixis Again. The Road to Defeating DMD. Two New Important IPOs

  Monday, May 09, 2016


A Judge is Offended About False Claims Against Gilead. Good News from Regeneron

  Monday, May 02, 2016


The FDA Approval of Exelixis Drug Cabometyx™ Is Indeed Great News

  Tuesday, April 26, 2016

Congratulation.   More...

Nectar Therapeutics and Seattle Genetics at the AACR Meeting

  Tuesday, April 19, 2016

Meaningful Presentations  More...

Recent Postings



BIOMARIN (BMRN) Advaxis (ADXS) Global Cell Therapeutics (GBT) Prolor Biotech (PBTH) MODERNA Incyte (INCY) Illumina (ILMN) Abbott Laboratories (ABT) IDERA (IDRA) Endometrial Cancer Idenix (IDIX) ACADIA (ACAD) NANTKWEST (NK) Vitae Pharmaceuticals (VTAE) ImmunoGen (IMGN) Cytokinetics (CYTK) Ridaforolimus Mirati Therapeutics (MRTX) Inovio (INO) Gilead (GILD) Intrexon (XON) Human Genome Sciences (HGSI) Benlysta (belimumab) Velcade (bortezomib) HALOZYME (HALO) Trastuzumab-DM1 Agenus (AGEN) Intercept (ICPT) Bellicum (BLCM) TOKAI (TKAOI) Tysabri Onyx (ONXX) Xoma (XOMA) Adaptimmune (ADAP) Amgen (AMGN) Intermune (ITMN) Herceptin Sanofi (SNA) ZALTRAP™ Auspex (ASPX) AERIE PHARMACEUTICALS REGULUS (RGLS) Ariad (ARIA) Sanofi-Aventis (SAN) AGOS (ARGS) Human Longevity (HLI) ISIS (ISIS) SUNESIS PHARMACEUTICALS (SNSS) CRISPR Therapeutics (CRSP) Elan (ELN) Jazz Pharmaceuticals (JAZZ) NOVOCURE (NVCR) Sanofi (SNY) Seattle Genetics (SGEN) Spike Therapeutics (ONCE) Sangamo (SGMO) KERYX (KERX) Vertex (VRTX) OSI (OSIP) Theravance (THRX) Rapamune ARCA (ABIO) Biocryst (BCRX) CompuGen (CGEN) Zerenex Ionis (IONS) Biogen Idec (BIIB) GlaxoSmithKline (GSK) Ocular Therapeutix (OCUL) KITE (KITE) Galena (GALE) Telaprevir RenenxBio (RGNX) Anadys (ANDS) JUNO (JUNO) Prosensa (RNA) SYNTA (SNTA) galapagos (GLPG) Aimmune Therapeutics (AIMT) Dynavax (DVAX) Bristol-Myers Squibb (BMY) SERES THERAPEUTICS (MCRB) Regeneron (REGN) C4 Therapeutics Roche (ROCHE) Theravance Bio Pharma (TBPH) ARGOS (ARGS) Alnylam (ALNY) VANDA (VNDA) Agenus (AGEN Array Pharmaceuticals (ARRY) INNOVIVA (INVA) NEKTAR (NKTR)) Multiple Myeloma AstraZeneca (AZN) Pluristem (PSTI) Sarepta (SRPT) Roche (RHHBY) ABBVIE (ABBV) PTC Therapeutics (PTCT) Revlimid (lenolidamide) Dendreon (DNDN) ADVENTRIX (ANX) Anacor (ANAC) Valeant Pharmaceuticals International (VRX) Sequenom (SQNM) Exelixis (EXEL) Ziofpharm (ZIOP) Alder Biopharmaceuticals (ALDR) GUARDIAN HEALTH Merck (MRK) Micromet (MITI) Genentech Editas (EDIT)